AASLD ISDA Practice Guideline on treatment of chronic hepatitis B.
가이드라인
4/5 보강
TL;DR
This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB, and was developed in compliance with the National Academy of Medicine standards.
연도별 인용 (2025–2026) · 합계 24
OpenAlex 토픽 ·
Hepatitis B Virus Studies
Hepatitis Viruses Studies and Epidemiology
Hepatitis C virus research
This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB, and was developed in compliance with the National Academy of Medicine standards.
APA
Marc G. Ghany, Calvin Q. Pan, et al. (2026). AASLD ISDA Practice Guideline on treatment of chronic hepatitis B.. Hepatology (Baltimore, Md.), 83(4), 974-997. https://doi.org/10.1097/HEP.0000000000001549
MLA
Marc G. Ghany, et al.. "AASLD ISDA Practice Guideline on treatment of chronic hepatitis B.." Hepatology (Baltimore, Md.), vol. 83, no. 4, 2026, pp. 974-997.
PMID
41186418 ↗
Abstract 한글 요약
[BACKGROUND AND AIMS] Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.
[METHODS] The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline.
[CONCLUSIONS] This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
[METHODS] The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline.
[CONCLUSIONS] This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.